1,423 results on '"Corley, Douglas A."'
Search Results
2. AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett’s Esophagus: Expert Review
3. Mission, Organization, and Future Direction of the Serological Sciences Network for COVID-19 (SeroNet) Epidemiologic Cohort Studies
4. Randomized Trial of Patient Outreach Approaches to De-implement Outdated Colonoscopy Surveillance Intervals
5. Combining Asian and European genome-wide association studies of colorectal cancer improves risk prediction across racial and ethnic populations
6. Assessment of genetic susceptibility to multiple primary cancers through whole-exome sequencing in two large multi-ancestry studies
7. Time Trends and Demographic Disparities in Helicobacter pylori Burden in a Large, Community-Based Population in the United States
8. Development and External Validation of a Prediction Model for Colorectal Cancer Among Patients Awaiting Surveillance Colonoscopy Following Polypectomy
9. Overall and Annual Postcolonoscopy Colorectal Cancer Rates in a Large Integrated Healthcare Setting: A Cross-Sectional Study
10. Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries
11. Risk-Stratified Screening for Colorectal Cancer Using Genetic and Environmental Risk Factors: A Cost-Effectiveness Analysis Based on Real-World Data
12. Impact of a scalable training program on the quality of colonoscopy performance and risk of postcolonoscopy colorectal cancer
13. Cross-cancer evaluation of polygenic risk scores for 16 cancer types in two large cohorts.
14. Evaluating Different Approaches for Calculating Adenoma Detection Rate: Is Screening Colonoscopy the Gold Standard?
15. Effect of Helicobacter pylori Eradication Therapy on the Incidence of Noncardia Gastric Adenocarcinoma in a Large Diverse Population in the United States
16. Pan-cancer study detects genetic risk variants and shared genetic basis in two large cohorts.
17. Post-Colonoscopy Colorectal Cancer Etiologies in a Large Integrated US Health Care Setting
18. Biopsy of Non-tumor Sites After Biopsy of a Colorectal Cancer is not Associated With Metachronous Cancers: A Case-control Study
19. Population-Level Identification of Patients With Lynch Syndrome for Clinical Care, Quality Improvement, and Research
20. Colorectal Cancer Screening After Sequential Outreach Components in a Demographically Diverse Cohort
21. Surveillance Colonoscopy Findings in Older Adults With a History of Colorectal Adenomas
22. AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett’s Esophagus: Expert Review
23. Collaborating on Data, Science, and Infrastructure: The 20-Year Journey of the Cancer Research Network.
24. Strategies to Improve Follow-up After Positive Fecal Immunochemical Tests in a Community-Based Setting: A Mixed-Methods Study
25. Risk of severe clinical outcomes among persons with SARS-CoV-2 infection with differing levels of vaccination during widespread Omicron (B.1.1.529) and Delta (B.1.617.2) variant circulation in Northern California: A retrospective cohort study
26. The association of bowel function, participation in life activities, and quality of life in rectal cancer survivors
27. Author Correction: Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries
28. Program Components and Results From an Organized Colorectal Cancer Screening Program Using Annual Fecal Immunochemical Testing
29. Predicting Risk of Colorectal Cancer After Adenoma Removal in a Large Community-Based Setting.
30. Projected Colorectal Cancer Incidence and Mortality Based on Observed Adherence to Colonoscopy and Sequential Stool-Based Screening.
31. Informative Presence in Electronic Health Record Data: A Challenge in Implementing Study Exclusion Criteria
32. Colorectal cancer screening based on predicted risk: a pilot randomized controlled trial
33. Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system
34. Survival by race and ethnicity among insured patients with early-onset colorectal cancer.
35. Cancer screening in the U.S. through the COVID-19 pandemic, recovery, and beyond
36. ANALYSES OF PREVENTIVE CARE MEASURES WITH INCOMPLETE HISTORICAL DATA IN ELECTRONIC MEDICAL RECORDS : AN EXAMPLE FROM COLORECTAL CANCER SCREENING
37. Understanding racial disparities in renal cell carcinoma incidence : estimates of population attributable risk in two US populations
38. Validation of the Updated Hepatocellular Carcinoma Early Detection Screening Algorithm in a Community-Based Cohort of Patients With Cirrhosis of Multiple Etiologies
39. Natural Language Processing for the Accurate Identification of Colorectal Cancer Mismatch Repair Status in Lynch Syndrome Screening
40. Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status
41. Validation of an Algorithm to Identify Patients at Risk for Colorectal Cancer Based on Laboratory Test and Demographic Data in Diverse, Community-Based Population
42. Association Between Levels of Sex Hormones and Risk of Esophageal Adenocarcinoma and Barrett’s Esophagus
43. Relative contribution of COVID-19 vaccination and SARS-CoV-2 infection to population-level seroprevalence of SARS-CoV-2 spike antibodies in a large integrated health system.
44. Creating pragmatic, rapid‐cycle, evidence‐based innovation: The Kaiser Permanente Northern California Delivery Science and Applied Research (DARE) program.
45. Ghrelin and Leptin Have a Complex Relationship with Risk of Barrett’s Esophagus
46. Data gaps and opportunities for modeling cancer health equity
47. Table S1 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
48. Data from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
49. Supplementary Figure 1 from Risk of Colorectal Cancer and Colorectal Cancer Mortality Beginning One Year after a Negative Fecal Occult Blood Test, among Screen-Eligible 76- to 85-Year-Olds
50. S1687 De-Implementation of Outdated Colonoscopy Surveillance Interval Recommendations Among Patients With Low-Risk Adenomas (DESIRE)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.